Safety issues with iron sucrose.
暂无分享,去创建一个
[1] J. Yee,et al. Iron sucrose: the oldest iron therapy becomes new. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[2] C. Chaimovitz,et al. Induction of protein oxidation by intravenous iron in hemodialysis patients: role of inflammation. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[3] G. London,et al. Iron Therapy, Advanced Oxidation Protein Products, and Carotid Artery Intima-Media Thickness in End-Stage Renal Disease , 2002, Circulation.
[4] R. Zager,et al. Parenteral iron formulations: a comparative toxicologic analysis and mechanisms of cell injury. , 2002, American journal of kidney diseases : the official journal of the National Kidney Foundation.
[5] T. Rabelink,et al. Ferric saccharate induces oxygen radical stress and endothelial dysfunction in vivo , 2002, European journal of clinical investigation.
[6] S. Kersting,et al. Nontransferrin‐bound iron in the plasma of haemodialysis patients after intravenous iron saccharate infusion , 2002, European journal of clinical investigation.
[7] J. Parkkinen,et al. Catalytically active iron and bacterial growth in serum of haemodialysis patients after i.v. iron-saccharate administration. , 2000, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.
[8] P. Geisser,et al. Pharmacokinetics of iron(III)-hydroxide sucrose complex after a single intravenous dose in healthy volunteers. , 1996, Arzneimittel-Forschung.